Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients

Not Applicable

Completed

• Conditions: Respiratory Tract Viral Infection

• Registration Number: NCT03389997
• Lead Sponsor: Poitiers University Hospital

Brief Summary

The purpose of this study is to assess the duration of the viral shedding in hematology and oncology patients after a respiratory tract viral infection. This duration has not been much studied in that population whereas it is probably longer than that in immunocompetent patients. Thereby it may be a source of transmission amongst these immunocompromised patients.

Detailed Description

The development of multiplex polymerase chain reaction (PCR) tests has greatly improved the diagnosis of respiratory tract viral infections by increasing its sensitivity and the diversity of viral species detected. However, there are few data concerning respiratory tract viral infections amongst hematology and oncology patients. Especially, the duration of viral shedding following an infection has not been much studied whereas it is a source of inter-individual transmission between immunocompromised patients who are more likely to develop severe disease.

Studies conducted so far concerned mainly hematology patients. They have shown that viral carriage could last up to one month and a half in some patients with hematological malignancy.

The aim of this study is to determine the duration of the viral shedding in patients from hematology and oncology units after a respiratory tract viral infection for the ten main viruses involved in order to better manage these infections and to better prevent their transmission.

Study Timeline

• Study Start: 2017-02-07
• Study First Submitted: 2017-12-21
• Study First Submitted QC: 2017-12-27
• Study First Posted: 2018-01-04
• Primary Completion: 2024-02-15
• Study Completion: 2024-02-15
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-18
• Last Update Posted: 2024-04-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

• Patient with solid organ cancer or haematological malignancy with or without chemotherapy
• Having symptoms of upper and/or lower respiratory tract infection
• Virus detected by PCR in nasal sample
• Signature of consent

Exclusion Criteria

• Hematological stem cell and solid organ recipients
• No health insurance
• protected people

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Nasal carriage of virus after a viral respiratory tract infection	Up to 1 year	Iterative nasal swab to assess the duration of that carryiage

Secondary Outcome Measures

Name	Time	Method
Correlation between TTV viral load and duration of viral shedding and severity of respiratory tract infection	2 years
Prevalence of viral coinfections	2 years
transmission of respiratory tract viral infections by relatives	2 years	with a survey filled by the patient
nosocomial transmission of respiratory tract viral infection	2 years
delay of chemotherapy due to respiratory infection	2 years
TTV viral load as a marker of immunodepression in oncology and hematology patients	2 years	TTV viral load at each visit
effect of influenza vaccine on viral shedding	2 years
risk factors to do severe form of respiratory tract infection	2 years
Prevalence of upper and lower respiratory tract infections	2 years
Prevalence of bacterial coinfections	2 years
respiratory complications due to respiratory tract viral infections	2 years
extra-pulmonary symptoms due to respiratory tract viral infections	2 years
survival after a respiratory tract viral infection	30 days

Trial Locations

Locations (1)

University Hospital of Poitiers; 🇫🇷 Poitiers, France